Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA’s Shuren: Staff Overburdened, Review Times Seeing Negative Effects

Executive Summary

The head of the US agency’s device center tells Medtech Insight that while he’s proud of his staff for taking on the extra workload due to the pandemic, product review times are slowing because resources are stretched thin.

You may also be interested in...



COVID-19-Related EUAs Bolster Record Number Of Novel Devices Greenlit By FDA

According to top FDA officials Jeff Shuren and William Maisel, regulators approved, cleared and authorized 132 novel devices up from its previous record of 106. It’s in large part due to EUAs for novel COVID-19 products issued last year.

Exclusive: Top Medical Device Lobbyist On User-Fee Talks, Biden And New Congress, Implementing MCIT Rule

The MDMA’s Mark Leahey talked with Medtech Insight about how the medical device industry responded to the COVID-19 pandemic, plans for working with a new administration and Congress, and hopes for the MDUFA negotiations.

Top CDRH Officials Tell EUA Holders: Don’t Procrastinate In Getting Products FDA-Approved

Makers of devices and tests granted emergency use authorization by the US FDA are being urged by the agency to not wait until the COVID-19 public health emergency is over to get their products approved – assuming they want to keep them on the market post-pandemic.

Related Content

Topics

UsernamePublicRestriction

Register

LL1135307

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel